Health Care & Life Sciences » Pharmaceuticals | Chugai Pharmaceutical Co. Ltd.

Chugai Pharmaceutical Co. Ltd. | Balance Sheet

Fiscal year is January-December. All values JPY Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
242,010
231,978
239,535
216,277
245,199
251,597
Total Accounts Receivable
128,387
159,887
158,717
167,483
175,001
179,559
Inventories
128,536
139,571
161,135
185,440
169,056
159,360
Other Current Assets
5,302
7,468
8,386
9,560
9,883
9,577
Total Current Assets
504,235
538,904
567,773
578,760
599,141
600,093
Net Property, Plant & Equipment
140,445
140,245
153,545
157,081
171,569
222,388
Total Investments and Advances
9,066
10,755
13,715
9,706
11,350
9,723
Intangible Assets
9,514
11,286
13,511
19,299
21,078
22,699
Other Assets
14,708
12,675
12,832
13,964
14,836
29,077
Total Assets
697,212
739,538
787,401
806,285
852,473
919,548
ST Debt & Current Portion LT Debt
38
29
131
135
129
Accounts Payable
35,939
35,386
41,173
42,529
38,434
Income Tax Payable
12,673
16,619
13,133
10,533
18,541
Other Current Liabilities
49,017
62,316
78,621
70,463
65,798
Total Current Liabilities
97,667
114,350
133,058
123,660
122,902
Long-Term Debt
195
185
604
510
207
Provision for Risks & Charges
3,351
4,726
4,332
10,930
11,333
Deferred Taxes
7,033
14,951
15,997
18,328
25,290
Other Liabilities
10,584
11,799
12,108
15,543
15,923
Total Liabilities
124,008
141,782
160,130
159,789
159,576
Common Equity (Total)
571,692
596,099
625,857
645,508
691,924
Total Shareholders' Equity
571,692
596,099
625,857
645,508
691,924
Total Equity
573,204
597,756
627,271
646,497
692,897
Liabilities & Shareholders' Equity
697,212
739,538
787,401
806,286
852,473
Accumulated Minority Interest
1,512
1,657
1,414
989
973

About Chugai Pharmaceutical Co.

View Profile
Address
Nihonbashi Mitsui Tower, 15/F
Tokyo Tokyo 103
Japan
Employees -
Website http://www.chugai-pharm.co.jp
Updated 07/08/2019
Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of the pharmaceuticals. Its operations are carried out through the following business divisions: Research, Development, Production, Marketing, Medical Affairs and Drug Safety. The Research division focuses its efforts on creating innovative drugs by using its competitive strengths that include proprietary antibody technologies and cutting-edge research resources.